Antagonic effect of ghrelin and LEAP-2 on hepatic stellate cell activation and liver fibrosis in obesity-associated NAFLD.

Silvia EzquerroCarlota TueroSara BecerrilVíctor ValentíRafael MoncadaManuel F LandechoVictoria CatalánJavier Gómez-AmbrosiFátima MochaCamilo SilvaKaren Piper HanleyJavier EscaladaGema FrühbeckAmaia Rodríguez

Published in: European journal of endocrinology (2023)

Ghrelin is an anti-fibrogenic factor blocking HSC activation induced by the most potent fibrogenic cytokine, TGF-β1, and LEAP-2. The imbalance between acylated ghrelin and ghrelin receptor antagonist LEAP-2 might contribute to maintain liver fibrosis in patients with obesity and NAFLD.

Keyphrases

liver fibrosis
insulin resistance
metabolic syndrome
weight loss
type diabetes
high fat diet induced
growth hormone
weight gain
transforming growth factor
stem cells
skeletal muscle
physical activity
mesenchymal stem cells
signaling pathway